Literature DB >> 12937825

[Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion].

Ping Zhou1, Sheng-Ying Wu, Cheng-Fan Yu, Hua Wang, Chao-Shu Tang, Li Lin, Wen-Jun Yuan.   

Abstract

To shed light on cardiac effects of the potent vasoconstrictive peptide urotensin II (U II), Langendorff-perfused isolated rat hearts were consecutively perfused with 0.1, 1 and 10 nmol/L U II, for 5 min at each dose, followed by 5-min washout. Moreover, isolated hearts subjected to 20-min global no-flow ischemia were reperfused with U II (1 or 10 nmol/L) for 20 min. Heart function parameters including heart rate, left ventricular pressure and dP/dt were monitored; content of protein and myoglobin, and activity of lactate dehydrogenase (LDH) in coronary effluent were determined; malondialdehyde (MDA) in myocardium and [(125)I]-U II binding sites in plasma membrane were measured after the completion of perfusion. The results showed that: (1) In normal rat hearts, the coronary flow was decreased and the heart function was suppressed by U II dose-dependently, and these changes were not abolished by washout. The leakage of cardiac protein, myoglobin and LDH increased with the increment of U II, but it diminished rapidly after washout. In contrast, MDA content in U II -treated myocardium was not statistically different from that in normal myocardium. (2) Ischemia-reperfusion caused significant decreases in coronary flow, suppression of heart function, and leakage of protein and LDH. In U II -reperfused hearts, all these disorders were significantly aggravated and myocardial MDA content significantly increased (P<0.01), to a greater extent in the presence of higher dose of U II. (3) The maximal binding capacity (B(max)) of U II receptors in plasma membrane from ischemia-reperfusion myocardium increased significantly as compared with that of normal myocardium (20.53+/-1.98 vs 14.65+/-1.78 fmol/mg pr, P<0.01), while Kd remained unchanged. These results indicate that U II caused injury to the isolated rat hearts under normal perfusion, and worsened the injury of the hearts under ischemia-reperfusion, in which U II receptors were up-regulated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937825

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  5 in total

1.  Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.

Authors:  Michael P Quaile; Hajime Kubo; Carie L Kimbrough; Stephen A Douglas; Kenneth B Margulies
Journal:  Circ Heart Fail       Date:  2009-01       Impact factor: 8.790

2.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

3.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

Review 4.  The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow.

Authors:  Ömer Şatıroğlu; Murtaza Emre Durakoğlugil; Mustafa Çetin; Yüksel Çiçek; Turan Erdoğan; Hakan Duman
Journal:  Interv Med Appl Sci       Date:  2016-12

5.  Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway.

Authors:  Sheng-Yong Luo; Shuo Chen; Yi-De Qin; Zhi-Wu Chen
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.